Global Dialysis

Renal Cancer Drug Pathway Analyzer 2015 - PR Newswire (press release)

LONDON, June 23, 2015 /PRNewswire/ -- There are today at least 238 targeted molecular therapies known to affect more than 240 specific intracellular signaling pathways for the treatment of renal cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 202 drug targets that are included in this drug-pathway analyzing tool. No less than 198 of these have been recorded with mutations and 39 drug targets have mutations which have been causally implicated in cancer.Pathway Coverage
- BioCarta# 223 Pathways
- KEGG# 185 Pathways
- NCI-Nature# 240 Pathways
- NetPath# 32 PathwaysPipeline Coverage
Marketed# 25
Pre-registration# 1
Phase III# 12
Phase II# 79
Phase I# 68
Preclinical# 26
Suspended# 3
Ceased# 95The continuous identification of drug targets and pathways that are altered in cancer is not only crucial for our understanding of cancer biology, but also to search for new targets for early diagnosis and improved treatment designs. Consequently, it has never before been as important to rapidly translate systems biology of disease and therapeutics to actionable pipeline decisions to ensure that the optimal market conditions exist by the time a candidate drug is commercialized.For this reason BioSeeker, a leader in pipeline analytics, has constructed this high-level drug-pathway analyzer which lets you interact with the renal cancer pipeline in a whole different than way than you ever done before. Its capabilities moves you beyond powerful competitive intelligence to an opportunity seeking tool which lets you, by means of both present and emerging scientific knowledge, analyze the renal cancer pipeline for interesting compounds which affect and/or fit your purposes, may it be benchmarking, in/out-licensing, combination therapy options, drug repositioning, indication expansion etc.You Use this Analyzer Tool in Renal Cancer to:* Map the competition and find suitable benchmarking/licensing drugs based on specific pathways and drug properties* Uncover potential indication expansion areas for your drug portfolio* Reveal repositioning opportunities for your older, shelved drugs* Evaluate the progression and success of targeting certain pathways by different tumor types* Investigate drugs which affect crosstalk between key pathways* Investigate different combination therapy options available to you in various cancer types. Use this tool to look for the most-efficient ways to combine your drug with other targeted agents.* Find possible adjuvant therapy settings with other drugs.This is how you do it:
In analyzing drug-pathway relationships this tool has three core modes:1. Select - You go right ahead and select any pathway for analysis2. Suggest - The tool can suggest pathways to you according to your pipeline specifications3. Compare - You can overlay any pathways with each other and do a comparative analysisYou can interactively analyze any renal cancer drug-pathway relationship by using up to four different pathway sources and further refine your analysis with up to 20 different pipeline parameters, including parameters such as presence of mutations, molecular function of targets, stage of development, sub-cellular localization and many more. Each parameter has multi-select options to them and can be used as either an inclusion parameter or exclusion parameter.User Reports with Graphics:
Each analysis report generated in the Drug Pathway Analyzer includes many different types of graphs and tables which can also be easily downloaded and dropped into applications such as PowerPoint for external presentations outside the tool.The Pathway Analyzer Comes Integrated with Pipeline Information
With a simple click you can easily and quickly get relevant information about the drug being included in a specific pathway. A typical drug profile reports on, depending on stage of development and available information:Drug Name & Synonyms
Presentation of drug name and synonymsPrincipal Company & Partners
Presentation of principal company and partners Target and Molecular Function of Target
Described target(s) is/are presented with:
Official Gene Symbol – Chromosome Location – Gene & Protein Name – Molecular FunctionTarget Localization
Described target(s) is/are presented with primary and alternate localizations.
Target Expression Profiles
Links to protein expression profile(s) of target(s) in various human tissues, cell lines and primary cells, including up to:
48 different normal tissue types
20 different types of cancer
47 cell lines
12 samples of primary blood cellsMutation
All targets are cross-referenced with the Catalogue of Somatic Mutations in Cancer (COSMIC). It is designed to store and display somatic mutation information and related details and contains information relating to human cancers.Biological Structures
The identity of available biological structures on drug targets was retrieved from the RCSB Protein Databank for you to easily review what available structures of drug targets exist.Targeted Pathways
Described target(s) is/are matched for the involvement in cellular pathways according to BioCarta, KEGG, NCI-Nature and NetPath.Mechanism
Drug mechanism of actionDevelopmental Projects
Summary field of developmental projects for the drug, including indication, developmental stage and status.
Example:
Cancer, myeloma – Phase II Clinical Trial – Active
Cancer, prostate – Phase III Clinical Trial – Ceased Drug Description
Short introduction to drugCompound Data
Compound type, Chemical name, CAS Number and molecular weightPatent Data
Available patent information related to the drug is presented here.Fillings and Approvals
Approvals and submissions
Analyst commentsDeals & Licensing
Collaborations and deals
Availability for licensingPhase IV Data
Available Phase IV development data, developmental history and scientific data.Phase III Data
Available Phase III development data, developmental history and scientific data.Phase II Data
Available Phase II development data, developmental history and scientific data.Phase I Data
Available Phase I development data, developmental history and scientific data.Phase 0 Data
Available Phase 0 development data, developmental history and scientific data.Preclinical Data
Available preclinical development data, developmental history and scientific data.Discovery Data
Available discovery development data, developmental history and scientific data.System Requirements
- Operating system: Windows (2000/XP/Vista/7/8) and Mac Users are offered Online Access Only
- Browser Application (Internet Explorer)
- Internet access (to access related internet resources) Download the full report:https://www.reportbuyer.com/product/1816745/

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

RELATED LINKS
http://www.reportbuyer.com

...

Share |

Empowering dialysis users and caregivers

Search for dialysis centres here

Jobs in dialysis

Dialysis travel

Dialysis information

Translate Global Dialysis

Dialysis centre search LOGIN HERE

Resources